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The SUMO pathway in pancreatic cancer: insights and
inhibition
Christian Schneeweis1, Zonera Hassan 1, Markus Schick2, Ulrich Keller2,3,4 and Günter Schneider 1,3
An urgent medical need to develop novel treatment strategies for patients with pancreatic ductal adenocarcinoma (PDAC) exists.
However, despite various efforts in the histopathological and molecular subtyping of PDAC, novel targeted or specific therapies
have not been established. Posttranslational modifications (PTMs) with ubiquitin-like proteins, including small ubiquitin-like
modifiers (SUMOs), mediate numerous processes that can contribute to the fitness and survival of cancer cells. The contribution of
SUMOylation to transcriptional control, DNA repair pathways, mitotic progression, and oncogenic signalling has been described.
Here we review functions of the SUMO pathway in PDAC, with a special focus on its connection to an aggressive subtype of the
disease characterised by high MYC activity, and discuss SUMOylation inhibitors under development for precise PDAC therapies.
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BACKGROUND
Although the introduction of active chemotherapeutic regimens
such as FOLFIRINOX and nab-paclitaxel with gemcitabine has
considerably advanced the therapy of pancreatic ductal adeno-
carcinoma (PDAC),1 the 5-year survival rate of 9% for patients with
this form of cancer remains unacceptably low.2 In addition to the
substantial toxicities associated with these aggressive chemother-
apeutic regimens, the low response rate in patients with
metastatic disease underscores the need to develop new
therapies.
PDAC heterogeneity, evident at numerous levels, is one
substantial hurdle for the establishment of novel therapies. Two
main subtypes of the disease have been consistently described:
the basal-like subtype, which shows a strong overlap with the
previously described squamous3 and quasi-mesenchymal sub-
types,4 and the classical subtype.5 A 2020 study, which includes
patients with advanced stages of the disease, further splits basal-
like PDACs into basal-like A and basal-like B and the classical
PDACs into a classical A and classical B type.6 Furthermore, a
hybrid type of the disease showing expression of mRNAs
belonging to identifier signatures of both main types has also
been identfied.6 Classical subtypes of PDAC show an enrichment
for stage I/II disease, whereas the basal-like A subtype is enriched
in metastatic disease and seems to be resistant to current
chemotherapies.6 The basal-like subtype is characterised by
activation of the MYC pathway together with pro-inflammatory
pathways, hypoxia networks, metabolic reprogramming, autop-
hagy, epidermal growth factor and transforming growth factor-β
(TGF-β) signalling and activation of the ΔNp63 pathway,3 as well
as being enriched in mutations in the tumour-suppressor TP53
and the lysine demethylase KDM6A and showing silencing of
endodermal identity transcription factors, such as GATA6 or
hepatocyte nuclear factor family members.3,6–11 The clear
differences in the molecular underpinnings of the PDAC subtypes
illustrate that understanding the biological mechanisms that drive
these subtypes and connect the different subtypes with novel
therapies represents one promising approach to improve the
outcome of the disease.
Posttranslational modifications (PTMs) are dynamic, reversible
enzymatic modifications that regulate processes such as protein
folding, cellular and subcellular localisation, activity, stability, and
interacting partners. PTMs can ensure quick adaption to the
continuously stressful extrinsic and intrinsic conditions faced by
cancer cells, and accordingly, PTM with ubiquitin and ubiquitin-
like molecules such as small ubiquitin-like modifier (SUMO) and
neural precursor cell expressed developmentally downregulated
(NEDD) can contribute to the fitness of cancer cells.12–15 Similar to
the process of ubiquitination, the ~11 kDa SUMO protein is
covalently conjugated to cellular proteins19 by an enzymatic
cascade mediated by the concerted action of the E1 SUMO-
activating enzyme (SAE), the E2-conjugating enzyme, UBC9, and a
limited set of E3 SUMO ligases (Fig. 1 and Box 1).
Thousands of cellular proteins can be SUMOylated18 to ensure a
highly dynamic regulation of cellular functions, such as protein
localisation, stability, interactions, as well as the activity of targets.
The protective role of the SUMO pathway for cells exposed to
various cell-intrinsic, including alterations in the cellular redox
state or DNA damage, and cell-extrinsic stresses,19 like hypoxia, is
reflected by the upregulation of SUMOylation in cancer cells.12
SUMOs are predominantly found within the nucleus, and
SUMOylation has thus been assumed—and in many instances
proven—to critically modulate cellular processes associated with
this compartment,20 ranging from the control of transcriptional
processes, DNA repair, and mitotic progression to the regulation
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of cancer-relevant signalling pathways such as those mediated by
TGF-β or nuclear factor-κB (NFκB). However, although a clear
enrichment of SUMOylation events in the nuclear compartment is
documented,18 cytosolic and membrane proteins can also
become SUMOylated, which can further contribute to cancer-
relevant functions of the pathway.21
The functions of the SUMO pathway in cancer have been
reviewed elsewhere in detail,12,13,20 so we will focus in this article
on the identified roles of the SUMO pathway in PDAC. We will
describe the known functions of the SUMO pathway in PDAC and
will summarise means and drugs to interfere with SUMOylation.
We will explain how the SUMO pathway is connected to the MYC
oncogene and how this relationship can be used to develop
precise therapies by applying a concept of synthetic dosage
lethality. Finally, we will describe future SUMO research directions
to translate basic findings to the clinic.
THE SUMO PATHWAY IN PDAC
The SUMO pathway has not yet been extensively analysed in
PDAC. However, the importance of the SUMO pathway in other
tumour entities, such as leukaemia or lymphoma, or many solid
cancers, including breast, colorectal, or lung cancers12 together
with investigations of the pathway in PDAC carried out over the
past decade, underscores the potential relevance of this pathway
with regard to the development of targeted therapies. Tissue-
based analysis and mRNA expression profiles have defined an
aggressive PDAC subtype that shows evidence of hyperactivity of
the core SUMO pathway and thereby links the SUMO pathway
with less-differentiated PDACs—the basal-like subtype—and an
unfavourable prognosis.22 Mechanistic studies in PDAC link the
SUMO pathway in particular with the response towards che-
motherapies and to mechanisms of treatment resistance.
Approximately 500 proteins were found to be modified by
SUMO1 in untreated MiaPaCa2 human pancreatic cancer cells.23
Notably, treatment of PDAC cells with chemotherapy altered the
SUMOylation state, and several target proteins became deSU-
MOylated or SUMOylated,23 underscoring the relevance of the
pathway in cellular stress responses. Smad nuclear interacting
protein 1 (SNIP1), for example, was found to be dynamically de-
and re-SUMOylated in response to gemcitabine treatment;23
SNIP1 has a role in the survival of MiaPaC2 cells under acute
therapeutic stress from gemcitabine treatment, which was found
to depend on its SUMOylation.23
Perturbed SUMOylation equilibria are common in drug-resistant
PDAC phenotypes. Promyelocytic leukaemia protein (PML) nuclear
bodies are known to be involved in the regulation of cellular
processes that are relevant to tumour suppression, such as DNA
repair and the DNA damage response (DDR).24 The function of
these nuclear organelles has been shown to be dependent on the
appropriate SUMOylation of the major structural component PML,
and hypoSUMOylation of PML in PDAC cells25 was associated with
increased activation of the NFκB pathway to mediate gemcitabine
resistance and increased activation of the cAMP response
element-binding pathway to mediate oxaliplatin resistance.25
Importantly, a distinct heterogeneity of PML expression and PML
SUMOylation was detected in patient-derived xenograft (PDX)
models. A score integrating total PML expression and PML
SUMOylation was positively correlated with patient survival. This
observation was interpreted by the authors as indication for a
decreased likelihood for responding to chemotherapy in the more
aggressive, PML-score low population.25 To directly test PML as an
indicator of chemotherapy responsiveness, PDX-derived cell lines
were investigated. Indeed, higher levels of secreted PML,
determined by proteomic analysis of secretomes, were connected
with increased drug sensitivity.25 Although PML containing
extracellular vesicles was described,26 the value of PML and its
SUMOylation status in secretomes as a diagnostic marker for
therapy responsiveness awaits further validation.
In addition, the E3-type SUMO ligase PIAS4 (protein inhibitor of
activated STAT protein 4) was shown to be overexpressed in PDAC
tumours and cell lines.27 Targeting PIAS4 by RNA interference
reduced PDAC cell growth. Tumour cells are exposed to limited
nutrient supply and hypoxia. Hypoxia is triggering adaptive
signalling pathways to assure survival and rewiring of cellular
metabolism, e.g. induction of glycolysis. The transcription factor
hypoxia-inducible factor-1 (HIF1), composed of the hypoxia-
regulated factor HIF1α and the constitutively expressed HIF1β,
and the E3 ubiquitin ligase von Hippel–Lindau (VHL), which
controls HIF1α protein abundance, are central regulators in this
adaptive process.28 Under hypoxic conditions of PDAC cells, PIAS4
contributes to SUMOylation and inactivation of VHL.27 This
Fig. 1 SUMOylation: a tightly balanced attachment of SUMOs to substrates. Small ubiquitin-like modifier (SUMO) proteins 1–3 undergo a
maturation step, followed by an ATP-dependent SUMO transfer to the SUMO1-activating enzyme subunit 1 (SAE1)–SAE2 heterodimer and
subsequent transfer to UBC9. UBC9 with contribution of E3 ligases transfers SUMOs to protein targets. The canonical functions of the pathway
are depicted.
Box 1: SUMOylation: a highly dynamic posttranslational
protein modification
Small ubiquitin-like modifier (SUMO)17 proteins 1–3 undergo a maturation step
mediated by cleavage through sentrin-specific peptidases (SENPs)16 to generate
the C-terminal diglycine (GG) motif. In addition, SENPs ensure reversibility of
SUMOylation and contribute to recycle SUMOs. The most intensively studied
SUMO proteins are SUMO1, SUMO2, and SUMO3, where the homology of SUMO2
and SUMO3 is 97%. In an ATP-dependent process, SUMOs are transferred to the
SUMO1-activating enzyme subunit 1 (SAE1)–SAE2 heterodimer. SUMOs are
bound via a thioester bond to SAE2/UBA2. Subsequently, SUMO is transferred to
the indispensable E2-conjugating enzyme of the cascade, UBC9 (UBE2I), again
forming a thioester bond. With contribution of E3 ligases (e.g. from the PIAS
family), SUMO is transferred to the ε-amino group of lysine within protein targets
via an iso-peptide bond. Protein targets can be mono-, poly-, or multi-
SUMOylated. The canonical functions12 of the pathway are depicted in Fig. 1.
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molecular event is needed for the complete stabilisation of HIF1α
in response to hypoxia. These data document the interaction of
the SUMOylation- and hypoxia-triggered pathways in the context
of PDAC, which further highlight the cross-signalling of both
pathways at multiple levels.12
INHIBITORS OF THE SUMO PATHWAY
Although the SUMO pathway has been implicated in cancer, only
a few drugs targeting SUMOylation have been developed so far.
Consistent with the existence of an enzymatic cascade to transfer
SUMOs to its targets, the SUMOylation machinery can be targeted
at several levels (Fig. 2) as well as at the level of SUMO maturation.
Inhibitors of the E1 SUMO-activating enzyme
Several natural products have been described and used to target
the SUMOylation pathway at the first activation step, which is
executed by the E1 enzyme. Such compounds include ginkgolic
acid and kerriamycin B, which have been shown to block the SAE
complex (Fig. 2).29 Ginkgolic acid inhibits the growth of PDAC cell
lines in the double-digit micromolar range in vitro and was also
shown to be active in an in vivo xenograft model.30 However,
mechanistically, ginkgolic acid was demonstrated to target a
pathway driving lipogenesis; and any specific effects of ginkgolic
acid on the SUMOylation machinery were not investigated in this
study.30 The ginkgolic acid structural analogue anacardic acid
inhibited the growth of PDAC cell lines in the double-digit
nanomolar range. At the molecular level, the chromatin-modifying
protein 1A was involved in the execution of the anacardic acid
response and some activation of the ataxia telangiectasia
mutated–p53 pathway was observed.31 Again, however, the role
of the SUMOylation machinery was not investigated in this study,
despite published evidence that anacardic acid reduces cellular
overall SUMOylation.32 For example, in acute myeloid leukaemia
(AML), anacardic acid reduced SUMO conjugation and increased
cell death, especially in AML cells that were resistant to standard
clinical chemotherapies.33
Due to the rather pleiotropic effects of naturally occurring
SUMOylation inhibitors, synthetic and more specific inhibitors of
the SAE complex have been developed. ML-792 and ML-93 form
covalent adducts with SUMOs and thereby block SAE and the
transfer of SUMOs to the E2 enzyme, UBC9.22,34 ML-792 and ML-93
in the nanomolar range reduce the fraction of SUMO-bound UBC9
and, consequently total protein SUMOylation, with no cross-
reactivity with the NEDDylation and ubiquitinylation
machineries;22,34 furthermore, when screened against 366 ATP-
dependent enzymes, ML-792 demonstrated specificity for the SAE
complex.34 ML-792 induces a failure of mitotic progression and
chromosome segregation, with a consequent increase in endor-
eduplication and polyploidy.34 Both ML-792 and ML-93 inhibit the
growth of PDAC cells and show a significant correlation in their
half-maximal growth inhibitory concentrations in a large panel of
murine PDAC cell lines.22 In sensitive pancreatic cancer models,
ML-93 was effective in the double-digit nanomolar range, which
was lower than the range observed using ML-792, resulting in the
accumulation of cells in the G2/M phase of the cell cycle and in
polyploidy with associated apoptosis.22 These results demonstrate
the importance of SUMOylation for proper mitotic progression.35
An ML-792/ML-93-derived SAE inhibitor, TAK-981, entered clinical
development in 2019, with Phase 1 trials recruiting patients with
any advanced or metastatic solid tumour and lymphoma
(NCT03648372 and NCT04074330).
In addition to SAE inhibitors that form adducts with SUMOs, a
novel covalent inhibitor, COH000, which binds to Cys30 of SAE2,
has been developed and characterised. COH000 does not
compete with SUMO1 or ATP for binding to SAE but instead
blocks the adenylation of SUMO36 by inducing conformational
changes in the enzyme, demonstrating an allosteric mode of
action.37 Functioning in the micromolar range in in vitro models,
this inhibitor has demonstrated preclinical efficacy in colon cancer
xenografts.36
Inhibitors of the E2-conjugating enzyme
In addition to the E1 enzyme complex, the indispensable E2
enzyme of the SUMOylation cascade, UBC9, can be targeted.29
Genetically targeting UBC9 demonstrated the impact of this
molecule as a fitness factor in PDAC.22 Although inhibitors of
UBC9, which include spectomycin B1, GSK145A, and 2-D0829 have
been described, no data for their efficacy in the context of PDAC
are available.
Potential SENP inhibitors?
As outlined earlier, the SUMOylation pathway is highly dynamic
and reversible, and various SENPs ensure the deSUMOylation of
target proteins and the recycling of SUMOs. Therefore, SENPs also
represent candidates for pharmacological targeting, and synthetic
inhibitors of these molecules are available.29 Despite conflicting
data with respect to the overexpression of SENP1 in PDAC,38,39
triptolide, a natural product known to downregulate the expres-
sion of SENP1 in prostate cancer cells,40 acts in the double-digit
nanomolar range in PDAC cell lines and has been shown to
activate checkpoint kinase 2 (CHK2) in drug-sensitive lines, leading
to inhibition of cellular growth.41 However, the direct involvement
of SENP1 in this triptolide-induced cellular response is unclear.
Furthermore, triptolide, which is also potent in selected in vivo
PDX PDAC models,42 is known to target the ERCC3 helicase, a
subunit of the transcription factor TFIIH43 to inhibit RNA
polymerase II-dependent transcription. Therefore, the effects of
triptolide on SENP1 seem rather indirect.
Inhibiting SUMO-dependent protein interactions
Another means of interfering with the SUMO pathway is to
prevent the recognition and interpretation of the SUMO code. The
information imparted by SUMOylation is recognised and trans-
lated into altered biology by non-covalent interaction with other
proteins that harbour a specific motif, the SUMO-interacting motif
(SIM). Affimer (Adhiron) technology—a system based on artificial
non-antibody scaffold proteins—was used to demonstrate that
synthetic proteins blocking SUMO-dependent protein–protein
interactions in a SUMO-isoprotein-specific fashion can be devel-
oped.44 For readers who are not familiar with this technology,
Fig. 2 Inhibition of the SUMOylation pathway. The figure depicts
inhibitors of the pathway, which block the SUMO-activating enzyme
or UBC9. Furthermore, peptidomimetic or non-peptidomimetic
inhibitors of the interaction of SUMOylated proteins with readers of
the SUMO code using the SUMO-interacting motif (SIM) are shown.
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please refer to refs. 45,46 Similarly, a SIM mimetic peptide coupled
to gold nanoparticles interacts with poly-SUMO-2/3 chains and
inhibits poly-SUMO-2/3-dependent protein–protein interactions.47
The involvement of the SUMO pathway in the control of the DDR
could explain how the gold nanoparticle SUMO-2/3 ligand
sensitises cancer cells to irradiation.47 Although non-
peptidomimetic small-molecule SUMO–SIM inhibitors are under
development,48,49 the therapeutic value in the context of PDAC is
currently not known.
MYC AND ITS CONNECTION WITH THE SUMO PATHWAY
The basic helix–loop–helix leucine zipper transcription factor MYC
dimerises with MAX, another basic helix–loop–helix leucine zipper
transcription factor, to bind to enhancer (E-) boxes in the
promoters of numerous genes. As an oncoprotein, MYC controls
the metabolism, growth, and proliferation of cancer cells.50
Witkiewicz and colleagues showed that amplification of MYC,
which was found in around 14% of patients with PDAC in their
study, is the sole copy number variation associated with the poor
survival of PDAC patients.51 Furthermore, another study showed
that MYC amplifications occur more frequently in liver metastasis
(12%) than in primary pancreatic tumours (4%) and lung
metastasis (6%), highlighting an important function of MYC along
the route to liver metastasis.52 This observation is underscored by
the demonstration that amplifications of MYC are positively
selected for during tumour progression,53 as well as the finding
that MYC activity is associated with the basal-like subtype of the
disease.3,6 Therefore, targeting MYC and MYC-dependent path-
ways could offer opportunities for novel therapies for patients
with advanced disease and very poor prognosis who might be
resistant to currently established standard therapies. Potential
approaches to target MYC in the context of PDAC, which include
bromodomain and extra-terminal motif (BET) inhibitors or MYC-
MAX dimerisation inhibitors, have been described previously,54–56
so we will focus here on the concept of MYC-associated synthetic
lethality.57
Synthetic lethality
Synthetic lethality usually refers to the situation in which
individually targeting each gene within a pair of genes is tolerated
but the combined inactivation induces a dramatic loss of cancer
cell fitness. Synthetic lethality can also occur between genes and
small molecules, as exemplified by the sensitivity of tumour cells
harbouring mutations in the DNA repair gene BRCA1/2 to poly-
ADP ribose polymerase (PARP) inhibitors and certain chemothera-
pies, such as platinum compounds.58,59 As the genetic lesion is
restricted to cancer cells, therapeutic concepts based on synthetic
lethality might open an exploitable therapeutic window. Indeed,
the benefits of platinum therapy or PARP inhibition have been
demonstrated in patients with BRCA1/2-mutated PDAC60–62
supporting the notion that synthetic lethality is relevant in PDAC
and that there is a need for preclinical and clinical research to
improve understanding of such concepts.
MYC and synthetic dosage lethal interaction
Notably, a specific kind of synthetic lethality, called synthetic
dosage lethality, defines a situation in which hyperactivity of one
gene generates a dependency on another gene product, and is
relevant in the context of the MYC pathway. Similar to the
situation for genetic lesions, the restriction of the hyperactivation
to cancer cells provides an exploitable therapeutic opportunity.
Accordingly, several unbiased genetic screens have validated the
concept of synthetic lethality associated with the MYC protein
family,57,63–70 and these screens have been supported by many
observations that postulate a synthetic lethal relationship of MYC
with the splicing machinery and the arginine methyltransferase
PRMT5,71 CHK1,72 cyclin-dependent kinase 1/2,73–75 Aurora
kinases,76–78 death-receptor engagement,79 PIM1,80,81 BET
inhibition,82,83 polo-like kinase 1,84 the mitotic machinery,85,86
and protein homoeostasis.87,88 These data suggest that MYC
drives the cellular machineries that are responsible for splicing,
protein homoeostasis, transcription, replication, or mitosis, to a
limit beyond which cells cannot cope with any additional stress
targeting these particular processes. Therefore, MYC marks
cancers with a specific set of therapeutic vulnerabilities, which
should consequently facilitate the stratification of patients for
precise therapeutic interventions.56
The MYC–SUMO connection
In 2012, an unbiased genetic screen demonstrated the synthetic
lethality of the SUMO pathway components SAE1 and SAE2 with
MYC,64 an observation subsequently corroborated in haematolo-
gical malignancies89 and small cell lung cancer (SCLC).90 Across
species, MYC-driven B cell lymphomas were characterised to
upregulate core components of the SUMOylation machinery,
including SUMO proteins, SAE1, SAE2, and UBC9. Inhibition of the
SUMO pathway triggered a G2/M phase arrest of the cell cycle,
polyploidy, and apoptosis in a MYC-specific manner. Genetic
interference with the pathway by targeting SAE2 demonstrated
therapeutic efficacy in murine and human B cell lymphoma
models in vivo.89 Furthermore, the knockdown of SAE2 in SCLC
cell lines with high MYC expression induced an increased
therapeutic effect compared to lines with low expression of the
oncogene.90 Work investigating the SUMO pathway in context of
MYC showed that the SUMOylation pathway is required to cope
with MYC-induced mitotic stress64 and that MYC hyperactivation
in the context of SUMO inhibition results in irregular spindle
activity, aneuploidy, and subsequent apoptosis.64 The concept is
illustrated in Fig. 3.
In contrast to the well-known functions of MYC in the G1 or S
phases of the cell cycle,91 the role of MYC in mitosis is less well
understood. Cells with high MYC levels show morphologically
altered spindles and are characterised by changes in the timing of
mitotic progression.92 Furthermore, increased MYC expression is
associated with misaligned chromosomes in metaphase with
subsequent lagging chromosomes in anaphase.93 This association
is relevant from the therapeutic view, as MYC was demonstrated
to be a critical determinant of cell fates occurring upon the
treatment of cells with various perturbations affecting mitosis.86,92
Such observations are clinically relevant, as demonstrated by the
increased responsiveness of MYC-amplified breast cancers to
docetaxel-containing neoadjuvant chemotherapies.94 Considering
that the SAE inhibitor ML-792 interferes with mitotic progression
and chromosome segregation,34 the increased potency of such
SAE inhibitors in MYC-hyperactive solid cancers seems well
explained.
At the molecular level, a 2020 study implicates the microtubule-
binding protein targeting protein for Xenopus kinesin-like protein
2 (TPX2) as an MYC-associated synthetic lethal gene.93 TPX2 is
required for spindle assembly during mitosis and the gene is
directly activated by MYC. Whereas normal cells need low
amounts of the protein for spindle assembly, cancer cell with
high MYC expression depend on TPX2 to efficiently form the
spindle and progress though mitosis.93 Importantly, the synthetic
lethal interaction of MYC is not restricted to TPX2. Synthetic
lethality between MYC hyperactivation and the mitosis regulators
BIRC5/survivin and EG5/kinesin‐5 was also demonstrated,93 and
MYC-associated synthetic lethal screens were enriched for mitotic
genes.64 Interestingly, many proteins identified in large-scale
proteomic screens to harbour multiple SUMO sites are mitotic
proteins, and BIRC5, EG5, and TPX2 can all be SUMOylated.95 In
fact, 39 SUMO sites have been identified in TPX2.96 This high
number could function to ensure proper spindle formation by
stabilising interactions with other spindle factors. As SUMOylation
plays an important role in the organisation of the spindle and
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kinetochore,95 it will be interesting to determine whether altered
SUMOylation of these mitotic proteins is involved in the response
of the cell to SUMO pathway inhibitors.
Importantly, the connection of MYC to the SUMO pathway is
relevant in PDAC. PDAC cells with higher MYC expression tend to
exhibit increased overall SUMO1 and SUMO2/3 protein SUMOyla-
tion and increased expression of core SUMO pathway genes.22 In
large panels of human and murine PDAC cell lines, ML-93
sensitivity correlated with MYC hyperactivity, and growth inhibi-
tion with ML-93 monotherapy was observed in a xenograft
model.22 In dynamic re-population assays, the selection pressure
of ML-93 treatment conferred a definite growth disadvantage on
the MYC hyperactive population, and the association of MYC
hyperactivity with an increased sensitivity to SAE inhibitors was
confirmed in conditional ‘MYC-on’ models, which depend on a
tamoxifen-activatable MYC oestrogen-receptor fusion protein.22
Again, also in the context of PDAC, the SAE inhibitor induced an
accumulation of cells in the G2/M phase of the cell cycle,
providing evidence that this particular targeted therapy is
triggering a mitotic vulnerability.
FUTURE DIRECTIONS
First evidence implicates that SUMO PTM represents a dynamic
biomarker for the response towards currently used chemothera-
pies.25 These findings offer the opportunity to validate the
expression of PML, for example, and to measure its SUMOylation
status in prospective clinical trials to select for chemotherapy
responders. The data demonstrating that various cellular stresses
induce dynamic SUMOylation and deSUMOylation events argue
for systematically studying SUMOylation targets as well as the
processes that are controlled by these events. This approach will
provide information to develop novel molecular-informed and
rational mechanism-based therapies. In addition, investigating the
specific role of SENPs, which, in normal cells, tightly control the
SUMOylation equilibrium, could provide information for additional
pharmacological intervention in MYC/SUMO-activated PDAC and
other cancers.
The development of SAE inhibitors clearly shows that specific
inhibition of the SUMO pathway is feasible. Despite the critical
importance of SUMOylation, SUMO inhibitors globally targeting
SAE are well tolerated in preclinical models22 and Phase 1 clinical
trials are currently ongoing. The investigation of such inhibitors in
the clinic (e.g. TAK-981) and the development of novel highly
specific SUMO inhibitors will allow for testing the principle of
SUMO inhibition in molecularly informed translational applica-
tions. The efficacy of clinical SUMO inhibitors will, however,
depend on the development of stratification concepts for
selecting PDAC patients with tumours that are particularly
sensitive to this approach.
Current data argue that SUMO inhibition is relevant for MYC-
hyperactivated PDACs. However, not all PDAC models with
evidence for MYC hyperactivation respond to the SAE inhibitors.22
This lack of response towards targeted therapies despite the
selection by a molecular marker is typically seen in a portion of
patients with gastrointestinal cancers in the clinic.97 However,
biomarker-driven therapy selection has been successful in other
cases.97,98 Therefore, to proceed with the concept of SUMO
inhibitors for PDAC, several additional issues must be addressed.
First, the response of PDAC cells to SUMO inhibitors must be
analysed in greater functional detail, which might additionally allow
to characterise the MYC-hyperactivated cancers with very high
sensitivity towards SUMO inhibition. Furthermore, other markers in
addition to MYC should be considered to define the SAE inhibitor-
sensitive proportion of PDACs more precisely. Multivariate models
have been shown to predict responses towards immunotherapies
with high accuracy.99 Considering that the full oncogenic power of
MYC is modulated by several co-factors,100 a similar approach might
point to a path for defining multivariate predictive models. Clinical
data from the past 5 years implicate the value of combining two or
more targeted therapies to treat solid cancers as exemplified for
colon cancer.98 Therefore, SUMO inhibitor combination therapies
could be developed in order to treat MYC-hyperactivated PDACs.
The demonstration that ML-792 does not synergise with che-
motherapies that act in the mitotic phase, including paclitaxel,34
argues for the need to systematically screen for such combination
therapies. In addition, the first-in-class SUMO inhibitor, TAK-981,
demonstrated immune-modulating properties.101,102 Considering
that MYC mediates complex cross-talk between tumour cells and
the tumour microenvironment,103,104 SUMO inhibitors should also
be tested in autochthonous immune-proficient models.
Current knowledge about the SUMO pathway and the response
to SUMO inhibitors in the context of PDAC will not immediately
enable SUMO pathway targeting therapies to be applied in the
clinic. However, the importance of the pathway, the existence of
specific inhibitors, and evolving concepts of synthetic lethality
should enable the development of such novel therapies for PDAC
and should be advanced for an aggressive subtype of the disease
that is largely resistant to current standard therapies.
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